Entity

Time filter

Source Type

Changhongjie, China

Shao N.,Tianjin Hospital of ITCWM | Cai Q.,Tianjin Hospital of ITCWM
Clinical and Translational Oncology | Year: 2015

Backgrounds: Compared to pure small cell lung cancer (SCLC), combined small cell lung cancer (C-SCLC) has its own characteristics. High neutrophil to lymphocyte ratio (NLR) and platelet–lymphocyte ratio (PLR) have been shown to be related to poor prognosis in several types of tumors. The aim of this study was to explore the prognosis value of NLR and PLR in patients with C-SCLC. Methods: A total of 112 patients diagnosed with C-SCLC between January 2000 and March 2009 were enrolled in the study. The clinicopathological parameters, laboratory analyses, and survival time were collected and analyzed. The correlation between NLR, PLR, and clinicopathological characters was analyzed. Univariate and multivariate analyses were performed to investigate the prognostic significance of these parameters for C-SCLC. Results: The pretreatment NLR was elevated in 37.5 % patients (NLR ≥ 4.15; n = 42; H-NLR). NLR was significantly related to disease stage (p = 0.033) and tumor recurrence (p = 0.014). The median overall survival (OS) and progression-free survival (PFS) were significantly worse in the H-NLR group (OS: 22.0 months vs 11.7 months, p = 0.001; PFS: 11.1 vs 6.0 months, p < 0.001). However, PLR at diagnosis was not associated with OS or PFS. Multivariate analyses indicated elevated NLR (HR = 1.6; p = 0.001), disease stage (HR = 1.6; p = 0.001), and performance status (HR = 1.8; p = 0.015) as independent prognostic factors. Conclusions: High pretreatment NLR (≥4.15) is a potential useful indicator for C-SCLC recurrence and predicts a poor long-term prognosis for C-SCLC, which should be considered in defining the prognosis with other well-known prognosticators in C-SCLC patients. © 2015, Federación de Sociedades Españolas de Oncología (FESEO). Source


Shao N.,Tianjin Hospital of ITCWM | Cai Q.,Tianjin Hospital of ITCWM
Tumor Biology | Year: 2015

High serum C-reactive protein (CRP) level is related to poor prognosis in several tumors. The aim of this study was to explore the prognosis value of serum CRP in patients with combined small-cell lung cancer (C-SCLC). The clinicopathological parameters of 112 C-SCLC patients from January 2000 to March 2009 were collected. The pretreatment serum CRP level was measured at diagnosis, and the correlation between serum CRP and clinicopathological characters was analyzed. Univariate and multivariate analyses were performed to investigate the prognostic significance of these parameters for C-SCLC. The pretreatment serum CRP level was elevated in 52.7 % of patients (E-CRP; n = 59), while (47.3 %) within the normal range (N-CRP; n = 53). There was a significantly worse disease stage (p = 0.037) and higher neuronal specific enolase (NSE) level (p = 0.014) in the E-CRP group. The median overall survival (OS) was significantly longer in the N-CRP group than in the E-CRP group (22.0 vs. 11.5 months, respectively; p < 0.001). Multivariate analyses indicated serum CRP (hazard ratio (HR) = 2.1; p < 0.001), the extent of disease (HR = 1.3; p = 0.039), performance status (HR = 1.8; p = 0.012), and NSE (HR = 1.2; p < 0.001) as independent prognostic factors. High pretreatment serum CRP level predicts a poor long-term prognosis for C-SCLC, which should be considered in defining the prognosis with other prognosticators in C-SCLC patients. © 2015, International Society of Oncology and BioMarkers (ISOBM). Source


Qiao M.,Tianjin Hospital of ITCWM | Hu G.,Tianjin Hospital of ITCWM
Tumor Biology | Year: 2015

The lysosome-associated protein transmembrane-4β-35 (LAPTM4B-35) protein has been indicated to be involved in solid tumors, while its role in small cell lung cancer (SCLC) remains unknown. The aim of this study is to investigate the LAPTM4B-35 protein expression and its clinical and prognostic role in SCLC patients. A total of 88 SCLC patients who underwent radical surgery between 2002 and 2010 were enrolled in the study. The level of messenger RNA (mRNA) and protein was detected from the fresh paired tumor specimens and adjacent normal tissues. The clinicopathological and survival data were collected. And the relationship between LAPTM4B-35 and clinicopathological features was analyzed. The prognostic value of LAPTM4B-35 for SCLC was investigated by univariate and multivariate analyses. The LAPTM4B-35 was overexpressed significantly in SCLC cancer tissues. The elevated protein expression was correlated strongly with clinical stage (p = 0.012) and tumor recurrence (p = 0.023). The 5-year overall survival and disease-free survival (DFS) were significantly worse in the patients with high LAPTM4B-35 level. Multivariate Cox analysis indicated that high LAPTM4B-35 expression was an independent prognostic factor for overall survival (OS) and DFS (p = 0.017 vs p = 0.011). LAPTM4B-35 overexpression was an independent factor in SCLC prognosis, which may be considered a potential useful marker in defining the SCLC prognosis. © 2015, International Society of Oncology and BioMarkers (ISOBM). Source


Xu T.,Tianjin Hospital of ITCWM | Liang G.,Tianjin First Center Hospital | Yang L.,Tianjin Hospital of ITCWM | Zhang F.,Tianjin Hospital of ITCWM
Clinical and Translational Oncology | Year: 2015

Backgrounds: It has been reported that metformin has an anticancer impact in various solid tumors, but its role in small cell lung cancer (SCLC) remains unclear. This study aimed to investigate the effect of metformin on survival in diabetic SCLC patients. Methods: A total of 79 SCLC patients with diabetes treated in our hospital between 2000 and 2010 were enrolled. The clinicopathological data and survival time were collected and evaluated. Univariate and multivariate analyses were used to investigate the association between metformin use and the survival of SCLC. Results: Among the 79 diabetic patients, 36 patients took metformin. The median OS and DFS were significantly better in the metformin group compared to non-metformin group (OS 18.0 vs 11.5 months, p < 0.001; DFS 10.8 vs 6.5 months, p < 0.001). Multivariate Cox analysis indicated that metformin use was an independent prognostic factor for long-term outcome (HR = 0.549, 95 % CI 0.198–0.978, p = 0.001). Conclusions: The prognosis of SCLC patients with diabetes treated with metformin was improved, which might be considered a potential useful anticancer drug in treating SCLC patients. © 2015, Federación de Sociedades Españolas de Oncología (FESEO). Source


Zhang F.,Tianjin Hospital of ITCWM | Zhang M.,Tianjin University | Hu G.,Tianjin Hospital of ITCWM | Cai Q.,Tianjin Hospital of ITCWM | Xu T.,Tianjin Hospital of ITCWM
Tumor Biology | Year: 2015

RABEX-5 has been studied in various solid tumors, but its role in combined small cell lung cancer (C-SCLC) remains unknown. This study aimed to investigate the expression, the potential relevance to clinicopathological characters and prognostic significance of RABEX-5 in patients with C-SCLC. Fifty-two C-SCLC patients who received radical surgery were enrolled in our study. The clinicalpathological data and survival time were reviewed. The mRNA and protein expression of RABEX-5 from the paired tumor tissues and adjacent normal tissues were determined, and its relationship with clinicalpathological variables and prognosis was analyzed. Univariate and multivariate analyses were performed to investigate the prognostic significance of RABEX-5 for C-SCLC. The mRNA and protein expression level of RABEX-5 was significantly elevated in C-SCLC tissues. The increased RABEX-5 protein expression was correlated with clinical stage (p = 0.011) and tumor recurrence (p = 0.006). The median OS and DFS was significantly shorter in the high RABEX-5 expression group compared to low RABEX-5 expression group (OS: 12.0 vs. 21.7 months, p = 0.014; DFS: 6.7 vs. 11.8 months, p = 0.005). Multivariate Cox analysis indicated that high RABEX-5 protein expression was an independent prognostic factor for OS and DFS (p < 0.001). RABEX-5 is a potential useful indicator and predicts a poor long-term prognosis for C-SCLC, which should be considered in defining the prognosis with other well-known prognosticators in C-SCLC patients. © 2015, International Society of Oncology and BioMarkers (ISOBM). Source

Discover hidden collaborations